Results 161 to 170 of about 5,263 (229)
Physiological and behavioral effects of dextroamphetamine on Beagle dogs
Journal of Veterinary Behavior: Clinical Applications and Research, 2011 The purpose of the study was to measure the effects of a dose of 0.2 mg/kg dextroamphetamine on body temperature, heart rate, motor activity, and associated behavior changes in Beagle dogs.
Clara Palestrini
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Journal of pharmacy and practice, 2022
Introduction: Methadone is a mu-opioid agonist with a delayed time to peak concentration that requires an extended period of monitoring following an overdose.
K. Weant, G. Hall
semanticscholar +1 more source
Introduction: Methadone is a mu-opioid agonist with a delayed time to peak concentration that requires an extended period of monitoring following an overdose.
K. Weant, G. Hall
semanticscholar +1 more source
Dextroamphetamine for epilepsy.
JAMA, 1975OUR EXPERIENCE supports the findings of the Boston Collaborative Drug Surveillance Program, prepared by Jick, 1 which did not confirm the relationship of amphetamine therapy to the development of Hodgkin disease described by Newell et al. 2 Over the past 30 years, we have prescribed the amphetamines, primarily dextroamphetamine sulfate (Dexedrine ...
S, Livingston, L L, Pauli
openaire +3 more sources
Dextroamphetamine, Catecholamines, and Behavior
Archives of Neurology, 1969THE CLINICAL usefulness of the amphetamines is based on their central nervous system (CNS) stimulating actions, eg, antidepressant, analeptic, and anorectic. It is not understood how the amphetamines exert their central effects, but experimental work in animals suggests a relationship with brain norepinephrine.
A H, Anton, M, Greer
openaire +2 more sources
Expert Review of Neurotherapeutics
Introduction The dextroamphetamine transdermal system (d-ATS) is a stimulant patch recently approved by the United States (U.S.) Food and Drug Administration for the treatment of attention-deficit/hyperactivity disorder (ADHD).
Ann Childress, Nicolas Vaughn
semanticscholar +1 more source
Introduction The dextroamphetamine transdermal system (d-ATS) is a stimulant patch recently approved by the United States (U.S.) Food and Drug Administration for the treatment of attention-deficit/hyperactivity disorder (ADHD).
Ann Childress, Nicolas Vaughn
semanticscholar +1 more source
Journal of Attention Disorders, 2020
Objective: A retrospective cohort study was performed to evaluate whether birthweight was less among infants of women taking amphetamine–dextroamphetamine during pregnancy at our academic institution.
Sherrill Rose +4 more
semanticscholar +1 more source
Objective: A retrospective cohort study was performed to evaluate whether birthweight was less among infants of women taking amphetamine–dextroamphetamine during pregnancy at our academic institution.
Sherrill Rose +4 more
semanticscholar +1 more source
Transdermal Dextroamphetamine (Xelstrym) for ADHD
The Medical Letter on Drugs and Therapeutics, 2023The FDA has approved a dextroamphetamine transdermal patch (Xelstrym – Noven) for once-daily treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥6 years old. Xelstrym is the first transdermal amphetamine product to be approved in the US.
openaire +2 more sources